Evidence map›Paper›PMID 29286542›Full record

Trial reportAlcoholism, clinical and experimental research2018

Effects of Initiating Abstinence from Alcohol on Daily Craving and Negative Affect: Results from a Pharmacotherapy Clinical Trial.

Kevin A Hallgren, Brianna C Delker, Tracy L Simpson

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Alcoholism, clinical and experimental research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Effectiveness of Naltrexone and Baclofen Combination in Reducing Craving among Patients with Alcohol Dependence: An Open-label Trial.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Article
  6. Early alcohol abstinence symptoms and the role of cumulative adversity.Alcohol, clinical & experimental research · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kevin A HallgrenDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington.ORCID 0000-0001-8386-3984
Brianna C DelkerDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington.
Tracy L SimpsonDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington.
University of Washington · US

Funding

Clinical Trials of the Adrenergic a-1 Antagonist Prazosin for Alcohol DependenceR01AA017184 · NIAAA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI SIMPSON, TRACY L. · 2008 to 2012
$1.4M
Developing a tool to assess, provide feedback, and facilitate discussion of mechanisms of change in frontline addiction treatmentK01AA024796 · NIAAA · UNIVERSITY OF WASHINGTON · PI HALLGREN, KEVIN A. · 2016 to 2020
$870k
NIAAA NIH HHS K01 AA024796NIAAA NIH HHS R01 AA017184
6 · The paper itself

Abstract

backgroundCraving and negative affect are distressing and commonly experienced during alcohol use disorder (AUD) treatment. Patients may assume that initiating abstinence will intensify their cravings and negative affect despite limited empirical data to support this assumption. This study extends and replicates, under improved methodological conditions, previous work that found reductions in daily craving associated with initiating abstinence.

methodsSeventy-eight adults (80.8% male, 57.1% Caucasian) in a clinical trial testing prazosin for AUD provided daily reports of drinking, craving, and negative affect for up to 12 weeks (mean = 64.77 daily reports). Participants were classified into 3 subgroups based on whether and when they initiated 14 days of continuous abstinence, including (i) "abstinence initiators" who quit drinking during treatment (n = 17), (ii) "already abstainers" who were abstinent at the start of treatment (n = 20), and (iii) "continued drinkers" who never initiated abstinence (n = 41). The timing and degree of change in craving and negative affect were compared across these groups using multivariate growth curve modeling.

resultsAll participant subgroups reported gradual reductions in craving over the course of treatment, with "abstinence initiators" reporting additional sudden reductions in craving upon initiating abstinence from alcohol. "Continued drinkers" reported higher levels of craving than "already abstainers" throughout the full course of treatment. Negative affect followed a different pattern of change, with "abstinence initiators" experiencing gradual reductions in negative affect after initiating abstinence but no changes prior to or immediately upon initiating abstinence, and with "already abstainers" and "continued drinkers" experiencing no changes in negative affect over time.

conclusionsInitiating abstinence is associated with immediate reductions in craving, followed by gradual reductions in both craving and negative affect. Results provide insight into the timing and magnitude of changes in theoretically and clinically important variables and may help patients anticipate when to expect improvement in craving and negative effect.

Indexed as

AffectAlcohol AbstinenceCravingAdrenergic alpha-1 Receptor AntagonistsAdultAlcoholismFemaleHumansMaleMiddle AgedMultivariate AnalysisPrazosinAdrenergic alpha-1 Receptor AntagonistsPrazosinAlcohol CravingDepressionDrinking UrgesNegative AffectSubstance Abuse Treatment

Identifiers

PMID29286542
PMCPMC5832597
OpenAlexW2776869494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.